Biotech startup Nuclera secures an extra $12M in Series C funding to accelerate protein production and compress drug discovery timelines.
Author: Elyse Christian
Zurich-based Ahead Health secures €5.1M to expand its data-driven preventive healthcare platform and strengthen its footprint across European markets.
Cambridge-based Nuclera is reshaping drug discovery by giving labs rapid, benchtop access to functional proteins through its eProtein Discovery platform.
As flashy apps plateau, the most valuable travel tech in 2026 will live deep in infrastructure, data and connectivity—far from the customer-facing interface.
From Web Summit to Slush, these 30+ European startup events in 2026 offer founders unmatched networking, fundraising and learning opportunities across the continent.
Finnish startup Avenue Biosciences secures €4.8M to help drugmakers manufacture complex proteins more reliably, targeting faster, cheaper and more scalable biopharmaceutical production.
Swiss startup FluoSphera secures CHF 1.15M seed funding to scale 3D human organ models designed to predict drug toxicity earlier and cut costly clinical trial failures.
French MedTech FineHeart raises €83M in private capital and EU grants to accelerate its implantable cardiac device for patients with advanced heart failure.
Femtech startup BrightHeart has raised €11M to develop AI-driven tools that aim to make prenatal screening more accurate, accessible, and affordable worldwide.
French biotech startup Spore.Bio secures multi‑million‑euro support from Google.org and launches an AI‑native research unit to accelerate safer, smarter biological innovation in Europe.
